Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) – USD ($)
 9 Months Ended
Apr. 30, 2022
Apr. 30, 2021
Operating activities    
Net loss $ (25,963,350)  $ (33,371,690) 
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 194,700  172,074 
Amortization of right-of-use asset 564,102  626,486 
Stock-based compensation 1,272,273  3,213,750 
Common stock issued for services 42,500  340,000 
Foreign currency exchange (gain) loss, net 399,338  (187,039) 
Gain on extinguishment of debt   (960,790) 
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,561,333  681,630 
Other long-term assets (290,876)  (28) 
Accounts payable and accrued liabilities (2,432,847)  (3,458,989) 
Accrued compensation related 22,226  (36,343) 
Operating lease liabilities (591,579)  (406,462) 
Net cash used in operating activities (25,222,180)  (33,387,401) 
Investing activities    
Purchase of property and equipment (244,857)  (259,662) 
Purchase of intangible assets   (495,000) 
Net cash used in investing activities (244,857)  (754,662) 
Financing activities    
Proceeds from issuance of common stock through ESPP 1,185  5,798 
Proceeds from issuance of common stock   57,004,411 
Payment of financing and offering costs (15,500)  (4,434,441) 
Proceeds from exercise of warrants   4,792,951 
Proceeds from exercise of stock options 202,800  489,580 
Purchase of shares under CGP and Sirtex stock purchase agreements   5,836,731 
Proceeds from co-promotion agreement   5,000,000 
Principal payments on note payable (1,109,378)  (497,319) 
Tax withholdings paid on equity awards (43,383)  (53,438) 
Tax shares sold to pay for tax withholdings on equity awards 42,949  54,191 
Net cash provided by (used in) financing activities (921,327)  68,198,464 
Effect of exchange rate changes on cash and cash equivalents (85,376)  (18,362) 
Net increase (decrease) in cash and cash equivalents (26,473,740)  34,038,039 
Cash and cash equivalents, at beginning of period 45,951,233  20,354,462 
Cash and cash equivalents, at end of period 19,477,493  54,392,501 
Supplemental disclosure for cash flow information:    
Interest 16,128  7,032 
Income taxes 2,950  4,492 
Noncash investing and financing transactions:    
Expiration of warrants   242,143 
Increase in right-of-use assets and operating lease liabilities resulting from contract modification   $ 338,819